ES2078234T3 - 1,3-dioxolanos sustituidos en posiciones 2 y 4, sintesis y uso de los mismos. - Google Patents

1,3-dioxolanos sustituidos en posiciones 2 y 4, sintesis y uso de los mismos.

Info

Publication number
ES2078234T3
ES2078234T3 ES89303537T ES89303537T ES2078234T3 ES 2078234 T3 ES2078234 T3 ES 2078234T3 ES 89303537 T ES89303537 T ES 89303537T ES 89303537 T ES89303537 T ES 89303537T ES 2078234 T3 ES2078234 T3 ES 2078234T3
Authority
ES
Spain
Prior art keywords
synthesis
positions
substituted
dioxolanes
dioxolanes substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89303537T
Other languages
English (en)
Inventor
Bernard Belleau
Dilop Dixit
Nghe Nguyen-Ba
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire Canada Inc
Original Assignee
IAF BioChem International Inc
Biochem Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22657287&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2078234(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by IAF BioChem International Inc, Biochem Pharma Inc filed Critical IAF BioChem International Inc
Application granted granted Critical
Publication of ES2078234T3 publication Critical patent/ES2078234T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Secondary Cells (AREA)
  • Peptides Or Proteins (AREA)
  • Paints Or Removers (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

LA INVENCION SE REFIERE A NUEVOS 1,3 - DIOXOLANOS SUSTITUIDOS EN LAS POSICIONES 2 - Y 4 -, QUE SON ESPECIALMENTE UTILES COMO AGENTES ANTIVIRICOS.
ES89303537T 1988-04-11 1989-04-11 1,3-dioxolanos sustituidos en posiciones 2 y 4, sintesis y uso de los mismos. Expired - Lifetime ES2078234T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17961588A 1988-04-11 1988-04-11

Publications (1)

Publication Number Publication Date
ES2078234T3 true ES2078234T3 (es) 1995-12-16

Family

ID=22657287

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89303537T Expired - Lifetime ES2078234T3 (es) 1988-04-11 1989-04-11 1,3-dioxolanos sustituidos en posiciones 2 y 4, sintesis y uso de los mismos.

Country Status (16)

Country Link
EP (1) EP0337713B1 (es)
JP (1) JP3085675B2 (es)
KR (1) KR0137023B1 (es)
AT (1) ATE129247T1 (es)
AU (1) AU631786B2 (es)
CA (1) CA1339609C (es)
DE (1) DE68924549T2 (es)
DK (1) DK175372B1 (es)
ES (1) ES2078234T3 (es)
GR (1) GR3017812T3 (es)
HK (1) HK5996A (es)
IE (1) IE71225B1 (es)
IL (1) IL89921A (es)
NZ (1) NZ228645A (es)
OA (1) OA09470A (es)
ZA (1) ZA892645B (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597824A (en) * 1987-11-03 1997-01-28 Abbott Laboratories Analogs of oxetanyl purines and pyrimidines
US6350753B1 (en) 1988-04-11 2002-02-26 Biochem Pharma Inc. 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US5684164A (en) * 1988-04-11 1997-11-04 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
UA45942A (uk) * 1989-02-08 2002-05-15 Біокем Фарма, Інк. 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція
IE904378A1 (en) 1989-12-20 1991-07-03 Abbott Lab Analogs of oxetanyl purines and pyrimidines
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5827727A (en) 1990-02-01 1998-10-27 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5914331A (en) * 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US6228860B1 (en) 1990-11-13 2001-05-08 Biochem Pharma Inc. Substituted 1,3-oxathiolanes with antiviral properties
US6369066B1 (en) 1990-11-13 2002-04-09 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes with antiviral properties
EP0560794B1 (en) * 1990-11-13 1996-09-18 Biochem Pharma Inc Substituted 1,3-oxathiolanes with antiviral properties
US5587480A (en) * 1990-11-13 1996-12-24 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
US5925643A (en) 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5179104A (en) 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
ZA923640B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
RU2235724C2 (ru) * 1992-02-12 2004-09-10 Эмори Юниверсити Способы разделения смеси энантиомеров
GB9226879D0 (en) * 1992-12-23 1993-02-17 Iaf Biochem Int Anti-viral compounds
US6005107A (en) * 1992-12-23 1999-12-21 Biochem Pharma, Inc. Antiviral compounds
US6444656B1 (en) 1992-12-23 2002-09-03 Biochem Pharma, Inc. Antiviral phosphonate nucleotides
CA2637774C (en) 1993-09-10 2011-07-19 Emory University Nucleosides with anti-hepatitis b virus activity
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5703058A (en) 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
EP0831852B1 (en) 1995-06-07 2006-11-29 Emory University Nucleosides with anti-hepatitis b virus activity
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
US5792773A (en) * 1996-11-15 1998-08-11 Yale University L-β-dioxolane uridine analog administration for treating Epstein-Barr virus infection
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
ATE267198T1 (de) * 1997-03-19 2004-06-15 Univ Emory Synthese und anti-hiv und anti-hepatitis virus aktivität von 1,3-oxaselenolan nucleosiden
KR100719606B1 (ko) 1998-02-25 2007-05-17 에모리 유니버시티 2'-플루오로뉴클레오사이드
EP1754710A3 (en) 1998-02-25 2007-12-19 Emory University 2'-Fluoroncucleosides
CA2340214C (en) 1998-08-12 2007-10-30 Triangle Pharmaceuticals, Inc. Method of manufacture of 1,3-oxathiolane nucleosides
US6979561B1 (en) 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
US6458773B1 (en) 1998-11-05 2002-10-01 Emory University Nucleoside with anti-hepatitis B virus activity
PT1140937E (pt) 1998-12-23 2004-04-30 Shire Biochem Inc Analogos de nucleosidos antivirais
KR20050005569A (ko) 1999-03-29 2005-01-13 샤이어 바이오켐 인코포레이티드 백혈병 치료방법
US6653318B1 (en) * 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
DE60011637T2 (de) * 1999-09-24 2004-11-11 Shire Biochem Inc., Laval Dioxolan nukleosidanalogen zur behandlung und vorbeugung von viralen infektionen
US6566365B1 (en) * 1999-11-04 2003-05-20 Biochem Pharma Inc. Method for the treatment of Flaviviridea viral infection using nucleoside analogues
EP1600452A3 (en) 1999-11-12 2008-09-10 Pharmasset, Inc. Synthesis of 2'-deoxy-L-nucleosides
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
AU1201502A (en) * 2000-10-13 2002-04-22 Shire Biochem Inc Dioxolane analogs for improved inter-cellular delivery
KR101150250B1 (ko) 2001-03-01 2012-06-12 아보트 래버러토리즈 시스-ｆｔｃ의 다형 및 기타 결정형
DE10335061B4 (de) * 2003-07-31 2005-11-17 Wacker-Chemie Gmbh Verfahren zur Herstellung von OH-geschützten [4-(2,6-damino-9H-purin-9-yl)-1,3-dioxolan-2-yl]methanol-Derivaten
BRPI0507363A (pt) 2004-02-03 2007-07-03 Univ Emory métodos para manufatura de 1,3-dioxolano nucleosìdeos
NZ567272A (en) 2005-09-26 2012-02-24 Pharmasset Inc Modified 4'-nucleosides as antiviral agents
US8895531B2 (en) 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
WO2008002676A2 (en) 2006-06-29 2008-01-03 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
EP3777832A1 (en) 2007-10-20 2021-02-17 Athenex, Inc. Pharmaceutical compositions for modulating a kinase cascade and methods of use thereof
US9675632B2 (en) 2014-08-26 2017-06-13 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL76546A (en) * 1984-10-12 1988-12-30 Warner Lambert Co 9-(heteroarylalkyl)-6-purine(thi)one derivatives,their preparation and pharmaceutical compositions containing them
ATE108794T1 (de) * 1985-05-15 1994-08-15 Wellcome Found Therapeutische nucleoside und deren herstellung.

Also Published As

Publication number Publication date
AU631786B2 (en) 1992-12-10
IE71225B1 (en) 1997-02-12
NZ228645A (en) 1991-09-25
DE68924549T2 (de) 1996-04-04
JP3085675B2 (ja) 2000-09-11
KR890016046A (ko) 1989-11-28
IL89921A0 (en) 1989-12-15
EP0337713A3 (en) 1990-11-22
AU3264489A (en) 1989-10-12
JPH01316375A (ja) 1989-12-21
OA09470A (en) 1992-11-15
DK172089D0 (da) 1989-04-10
DE68924549D1 (de) 1995-11-23
EP0337713A2 (en) 1989-10-18
KR0137023B1 (ko) 1998-04-25
ATE129247T1 (de) 1995-11-15
DK172089A (da) 1989-10-12
CA1339609C (en) 1997-12-30
GR3017812T3 (en) 1996-01-31
IL89921A (en) 1993-08-18
DK175372B1 (da) 2004-09-13
ZA892645B (en) 1989-12-27
IE891136L (en) 1989-10-11
HK5996A (en) 1996-01-19
EP0337713B1 (en) 1995-10-18

Similar Documents

Publication Publication Date Title
ES2078234T3 (es) 1,3-dioxolanos sustituidos en posiciones 2 y 4, sintesis y uso de los mismos.
FI906045A0 (fi) Kvaevehaltiga spirocykliska foereningar.
DE68911195D1 (de) Wenig klebende Zusammensetzungen von Perfluoropolyether.
ES2080739T3 (es) Nitro-compuestos insecticidamente activos.
MX26184A (es) Derivados de benzopirano y analogos heterociclicosde los mismos.
FI895514A7 (fi) Antiviraaliset aineet
FI870492A7 (fi) Vaermevaexlare och saett att framstaella en saodan
DK430689D0 (da) 2-aza-4-(alkoxycarbonyl)spiro(4,5)decan-3-oner
FI892222A0 (fi) Peptidalkoholer med antikoagulantverkan.
DK80990A (da) Sulfonylderivater af thien-triazol-diazepin
DE69026645D1 (de) Verwendung schäumbarer Zusammensetzungen
DK104389D0 (da) Anvendelse af imidazolderivater
FI895977A7 (fi) 3,4-hydroksibentsoyloksipropanoliaminien esilääkeaine
ES2060944T3 (es) Derivados de 2,5,6,7-tetranor-4,8-inter-m-fenileno de pgi2 (prostaglandina i2).
DK0532629T3 (da) 1-Piperidinyl-alkanoylarylsulfonamid-derivater
DK228990D0 (da) Fremstilling af 2,6-dioxopiperidinderivater
DK233689D0 (da) Fremstilling af 2,3-dideoxynukleosider
FR2629696B1 (fr) Table repliable
IT208148Z2 (it) Tavolo ripiegabile
IT8823009A0 (it) Procedimento per la reversione della tossicita' della bromovinildesossiuridina (bvudr)
BR6802719U (pt) Disposicao construtiva de quadros
BR6800664U (pt) Mesa desmontavel portatil
BR6802292U (pt) Mesa escolar regulavel
LV5507A3 (lv) 4,5.-Dihidrooksazolu atvasinajumu iegusanas panemiens
BR6800958U (pt) Mesinha portatil desmontavel

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 337713

Country of ref document: ES